Immunovia AB

As of June 30, 2026, Immunovia AB carries a market capitalization of 131.17M, placing it among publicly traded companies globally. Its enterprise value stands at 99.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Immunovia AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Immunovia AB has 672.67M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 90.96, and the price-to-book ratio stands at 5.55.

These figures are as of June 30, 2026. The EV/Sales ratio of 82.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 99.54M versus a market cap of 131.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Immunovia AB maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.84, indicating elevated leverage, while an interest coverage ratio of -13.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Immunovia AB posted a negative return on equity (ROE) of -426.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -213.15, reflecting losses generated across the asset base. The company generates approximately 100,833.33 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Immunovia AB's stock has declined approximately 75.21% over the past 52 weeks. The 50-day moving average sits at 0.12, while the 200-day moving average is 0.17.

Over the twelve months ended June 30, 2026, Immunovia AB generated 1.21M in revenue and converted that into -88.33M in net income, yielding earnings per share of -0.16. EBITDA reached -80.86M, while operating income came in at -82.74M.

As of June 30, 2026, Immunovia AB holds 34.90M in cash and equivalents against 3.27M in total debt, resulting in a net debt position of -34.90M. Total book value stands at 23.64M, with working capital of 13.92M providing operational flexibility.

Immunovia AB produced -77.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.56M in capital expenditures, free cash flow totaled -82.91M - equivalent to -0.15 per share.

Over the twelve months ended June 30, 2026, Immunovia AB posted a gross margin of 56.94, reflecting its pricing power and cost economics. The operating margin of -6,837.93 and net profit margin of -7,300.33 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -75.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -67.97, meaning Immunovia AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Immunovia AB's most recent stock split took place on October 2, 2025 with a 360:463 split ratio.

As of June 30, 2026, Immunovia AB has an Altman Z-Score of -47.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.